Favorable outcome with hyper-CVAD in lymphoblastic lymphoma (LL)

6597 Background: Outcome with LL has improved with use of more intensive chemotherapy regimens designed for acute lymphoblastic leukemia (ALL). Methods: From April 1992 to November 2001, 33 patients (pts) with newly diagnosed LL were treated with standard (n=22) [Kantarjian et al, J Clin Oncol 15:547, 2000] or modified (n=11) [Thomas et al, Blood 102:880a, 2003] hyper-CVAD regimens. Courses of hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone were alternated with methotrexate (MTX) and ara-C. The modified regimen inserted liposomal daunorubicin and ara-C for course 2. Mediastinal irradiation (XRT) was planned for bulky mediastinal disease. Intrathecal CNS prophylaxis alternated MTX and ara-C on days 2 and 7 of the first 3–4 courses. POMP (6-MP, vincristine, MTX, prednisone) maintenance was given for at least 2 years, interrupted by intensifications (MTX/asparaginase with or without hyper-CVAD depending on regimen). Results: Median age was 28 yrs (range, 17–59) and 82% were ma...